Physician profile
William J Brown
NPI 1790769172
$7,677.02
in general payments reported to CMS, 2019-2025
50 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,028 · 2020: $794 · 2021: $1,307 · 2022: $1,277 · 2023: $1,105 · 2024: $1,013 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,270.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,083.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,027.39 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $946.01 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $680.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $477.10 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $437.53 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $290.78 | 2019-2025 | |
| Amgen INC. | $234.78 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.20 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $160.07 | 2019-2025 | Veozah, Myrbetriq |
| Lundbeck LLC | $155.26 | 2024-2025 | Rexulti |
| Abbott Laboratories | $150.09 | 2019-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $134.04 | 2020-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $133.09 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.26 | 2020-2024 | Xifaxan |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.